13 slides from Amarantus Bioscience's shareholder meeting presentation, Aug 3, 2015
Slide 1: Annual Meeting of Shareholders August 3, 2015
Ticker: OTCQX:AMBS www.amarantus.com Annual Meeting of Shareholders August 3, 2015
Slide 2: Forward-Looking Statements
Forward - Looking Statements This presentation contains “ forward - looking statements ” within the meaning of the “ safe - harbor ” provisions of the Private Securities Litigation Reform Act of 1995. Such statements involve known and unknown risks, uncertainties and other factors that could cause t
Slide 3: Holding Company Business Model Fuels Rich Pipeline
AMBS Holding Company Business Model Fuels Rich Pipeline Our Vision : Identifying undervalued assets, de - risking and advancing to key value driving events: 3 ® ® Screening Expertise Neurological Disorders Parkinson’s Disease Adult ADHD Alzheimer’s Aggression Multiple Sclerosis Orphan Indications Re
Slide 4: Building Value into Therapeutics Pipeline to Reach Transformational Milestones
Building Value into Therapeutics Pipeline to Reach Transformational Milestones 4 Program Preclinical Phase 1 Phase 2 Phase3 Market ESS Intractable Severe Burns Eltoprazine Parkinson’s PD - LID Eltoprazine Adult ADHD Eltoprazine Alzheimer’s Aggression MANF Retinitis Pigmentosa MANF Parkinson’s Diseas
Slide 5: Recent ESS Acquisition to Add Significant Value
Recent ESS Acquisition to Add Significant Value • Autologous, skin graft replacement for 50 + % TBSA severe burns • Biologics/drug regulatory pathway in office of combination products • Orphan Drug Designation received in 2012 • Active IND as of May 2014 • Partially funded by US Gov’t grant : AFIRM
Slide 6: ESS: Recent Milestone Achievements
ESS: Recent Milestone Achievements x Completed acquisition of Cutanogen Corporation for exclusive rights to ESS x Preparation underway to commence Phase 2 study x First site initiation underway x Signed CRADA Agreement providing non - dilutive resources x Strong KOL support NEXT MILESTONES ▪ Initiat
Slide 7: Eltoprazine: Recent Milestone Achievements
Eltoprazine: Recent Milestone Achievements x Published Phase 2a clinical study results in BRAIN for the treatment of PD - LID x Opened an IND application with the neurology division of the FDA to advance Eltoprazine into Phase 2b clinical studies x Completed Investigator Meetings in US and EU x Ente
Slide 8: MANF: Recent Milestone Achievements
MANF: Recent Milestone Achievements x Announced the successful delivery and distribution of MANF in a preclinical model to brain areas involved in Parkinson's disease , further solidifying the rationale for its preclinical development as a potential disease - modifying treatment for PD x Entered int
Slide 9: Amarantus Diagnostics Preparing for Strategic Transaction
Amarantus Diagnostics Preparing for Strategic Transaction • LymPro Test ® : O ptimizing IUO marketing and CLIA strategy • MSPrecise ® : Finalizing commercial strategy for staged product launch • Georgetown assays position to control significant market share in the emerging AD IUO blood diagnostics m
Slide 10: Up-listing to NASDAQ is a Priority
Up - listing to NASDAQ is a Priority x Submitted the listing application x Currently completing the listing process x Awaiting a formal response from NASDAQ 10
Slide 11: Next Steps for Amarantus
Next Steps for Amarantus » Uplist to NASDAQ as rapidly as possible » Focus on Operational Excellence with therapeutic programs to advance to key data milestones » Complete strategic transaction with Amarantus Diagnostics 11 We are prepared to enter our next phase of growth!
Slide 12: Q&A
12 Q&A Amarantus Bioscience
Slide 13: Annual Meeting of Shareholders August 3, 2015
Ticker: OTCQX:AMBS www.amarantus.com Annual Meeting of Shareholders August 3, 2015